信立泰：SAL0137 获得临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein (a) levels, which are independent risk factors for various cardiovascular diseases [1] Group 1: Drug Development - The clinical trial approval allows the company to proceed with testing SAL0137 for its efficacy in treating elevated Lp(a) levels [1] - Preclinical studies indicate that SAL0137 has potential in addressing elevated Lp(a), suggesting significant development prospects [1] Group 2: Health Implications - Elevated Lp(a) levels are linked to increased risks of coronary heart disease, ischemic stroke, peripheral vascular disease, coronary artery calcification, and calcific aortic valve stenosis [1] - Lp(a) contributes to cardiovascular disease risk through mechanisms such as promoting atherosclerosis, inflammation, and thrombosis [1]